U.S. In Vitro Fertilization Market

U.S. In Vitro Fertilization Market Size and Share:

The U.S. in vitro fertilization market size was valued at USD 161 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 385.6 Million by 2033, exhibiting a CAGR of 9.1% from 2025-2033. There are several factors that are driving the market, which include the rising prevalence of chronic diseases like obesity, diabetes, and polycystic ovary syndrome (PCOS), unhealthy dietary habits, technological innovations, and advancements in genetic testing for enhanced success rate and patient care.

Individuals in the United States are increasingly postponing parenthood for job, financial, or personal reasons. Fertility naturally falls with aging due to lower egg and sperm quality. This is leading to a greater reliance on assisted reproductive technologies (ART), such as in vitro fertilization (IVF), to address age-related infertility issues. In addition, the availability of improved techniques like egg freezing for later use contributes to this trend. Delayed parenthood is also associated with improved awareness and acceptance of fertility treatments, which drives demand for IVF as a viable option for people looking to start families later in life.

The mandate for insurance coverage of reproductive treatments in certain US jurisdictions helps to improve access to IVF services. Policies now usually cover diagnostic examinations, medications, and IVF procedures, which benefit in lowering cost hurdles for individuals. States such as Massachusetts, New York, and Illinois provide comprehensive fertility coverage, encouraging more people to seek treatment solutions. In line with this, these insurance reforms are expanding the patient base, enabling middle-income families to consider treatment options. This shift is making fertility care more reasonable, which is contributing to the market growth.

U.S. In Vitro Fertilization Market Trends:

Rising Cases of Chronic Diseases

The increasing prevalence of health conditions like obesity, polycystic ovary syndrome (PCOS), and diabetes is catalyzing the demand for fertility treatments like IVF. Obesity is a growing public health concern that directly affects reproductive health. Excess weight disrupts hormonal balance, leading to irregular ovulation in women. In men, obesity is linked to lower testosterone levels, poor sperm quality, and reduced libido. Moreover, PCOS is one of the leading causes of infertility among women of reproductive age. Women with PCOS usually face problems conceiving naturally. Furthermore, high blood sugar levels disrupt the reproductive hormone axis, causing irregular ovulation and affecting uterine health in women. Men with diabetes often experience issues such as erectile dysfunction, retrograde ejaculation, and reduced sperm quality. As per the International Diabetes Federation (IDF), around 34,755.3 people with age 20-79 years are expected to have diabetes in 2030.

Technological Innovations

Continuous improvements in IVF processes and techniques aid in increasing success rates, making the process more efficient, safe, and accessible. Modern culture mediums are designed to accurately replicate the uterine environment. Innovations in time-lapse monitoring and microfluidic devices help to refine the conditions within the culture. Companies are also forming agreements with other stakeholders to combine modern technology and improve patient care. For instance, on 12 March 2024, Alife Health, a leading fertility technology company specializing in the development of AI tools for IVF, announced a groundbreaking partnership with Boston IVF, a leading fertility clinic with more than 25 locations across the US, to pilot the country’s first AI tool for IVF medication optimization. Boston IVF will implement Alife’s Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.

Advancements in Genetic Testing

The research report of the IMARC Group states that the United States genetic testing market reached USD 5.3 Billion in 2024. Preimplantation genetic testing (PGT) is emerging as a revolutionary component of IVF, greatly increasing success rates and giving families with genetic health assurances. Individuals or couples with known genetic predispositions can use PGT to screen for hereditary illnesses. Conditions like cystic fibrosis, Tay-Sachs disease, and sickle cell anemia can be detected early. PGT reduces the chance of passing on genetic abnormalities to offspring by selecting embryos that do not have these conditions.

U.S. in Vitro Fertilization Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the U.S. in vitro fertilization market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on product, procedure type, cycle type, and end user.

Analysis by Product:

• Reagent
  • Cryopreservation Media
  • Embryo Culture Media
  • Ovum Processing Media
  • Sperm Processing Media
• Instrument
  • Imaging Systems
  • Incubators
  • Cryosystems
  • IVF Cabinet
  • Ovum Aspiration Pump
  • Sperm Separation Systems
  • Micromanipulator Systems
  • Others
• Accessories
   

Reagent is essential for ensuring optimal conditions for gamete handling and embryo development. Advancements in reagent formulations, such as improved culture media, that mimic natural uterine environments, aid in enhancing embryo viability and pregnancy success rates. The increasing adoption of PGT is catalyzing the demand for specialized reagents.

Technological advancements are leading to more precise and reliable instruments such as time-lapse imaging system that allow continuous monitoring of embryos. Innovations in micromanipulation tools are improving techniques like intracytoplasmic sperm injection (ICSI), enhancing the efficiency and success rates of IVF treatments.

Accessories include catheters, needles, and other consumables necessary for various stages of IVF procedures. The recurring need for these accessories in every cycle ensures a steady market demand. Improvements in the design of accessories like minimally invasive (MI) needles and flexible catheters are improving procedural safety and patient comfort.

Analysis by Procedure Type:

• Fresh Donor
• Frozen Donor
• Fresh Non-donor
• Frozen Non-donor
   

Fresh donor procedures involve the use of freshly retrieved eggs or sperm from donors. These are immediately used for fertilization without prior freezing. This approach is often preferred when donors are available, as fresh gametes tend to have higher viability compared to frozen ones.

Frozen donor methods make use of donor eggs or sperm that have previously been cryopreserved. Advances in cryopreservation techniques and notably vitrification are increasing the longevity and viability of frozen gametes. This method offers greater flexibility in timing for recipients and eliminates the need for cycle synchronization.
Fresh non-donor treatments use newly obtained eggs or sperm from the intended parents. These are immediately used to fertilize and transfer embryos. This approach is popular among IVF couples because fresh gametes offer the best chances of fertilization.

Frozen non-donor procedures utilize cryopreserved eggs, sperm, or embryos from the intended parents. This approach allows for embryo banking and flexibility in planning subsequent cycles. The ability to freeze embryos for later use reduces the need for repeated ovarian stimulation and retrieval, lowering costs and physical strain on patients.

Analysis by Cycle Type:

• Conventional IVF
• IVF with ICSI
• IVF with Donor Eggs
   

Conventional IVF involves combining eggs and sperm in a laboratory setting, allowing fertilization to occur naturally. This method is most suitable for patients with unexplained infertility or mild male factor infertility. The simplicity and relatively lower cost of conventional IVF make it a preferred option for many couples.

IVF with ICSI involves the direct injection of a single sperm into an egg. This method is particularly beneficial for addressing severe male factor infertility such as low sperm count or poor motility. ICSI is becoming a widely adopted procedure due to its high fertilization success rates, even when sperm quality is suboptimal. The technique is also utilized in cases where previous conventional IVF cycles have failed.

IVF with donor eggs is a specialized cycle type used when the intended mother’s eggs are unsuitable for fertilization, often due to advanced maternal age, ovarian insufficiency, or genetic conditions. Donor eggs are fertilized with the partner’s or a donor’s sperm and the resulting embryos are transferred to the intended mother. This option offers a higher chance of success compared to using compromised eggs.

Analysis by End User:

• Fertility Clinics
• Hospitals
• Others
   

Fertility clinics are specialized facilities dedicated exclusively to reproductive health and assisted reproductive technologies (ART). These clinics offer comprehensive services including diagnostics, counseling, and advanced IVF procedures. Their focus on reproductive treatments allows for high-quality and personalized care, making them the preferred choice for most patients.

Hospitals also play a significant role in the IVF market, offering reproductive services as part of broader healthcare facilities. Patients often choose hospitals for IVF treatments owing to their well-established infrastructure, availability of multidisciplinary teams, and access to emergency medical support. Hospitals are particularly favored for high-risk or complex cases where comprehensive medical care is essential.

Regional Analysis:

• Northeast
• Midwest
• South
• West
   

The Northeast region in the IVF market is driven by advanced healthcare systems, high patient awareness, and widespread availability of fertility clinics. States like Massachusetts and New York often offer robust insurance coverage for fertility treatments. The region also benefits from its high concentration of medical research institutions, fostering innovation in IVF technologies.

The Midwest region’s IVF market is supported by an increasing number of fertility clinics and improving awareness about ART. Ongoing legislative efforts in the region are helping improve access. Affordability and a growing focus on rural healthcare solutions are contributing to the market growth.

The South is witnessing significant growth because of its large and diverse population, coupled with rising infertility rates. The region’s growing healthcare infrastructure and the expansion of fertility clinics into suburban and rural areas are key drivers. States like Texas and Florida are emerging as key contributors to the IVF market in this region. 

The West is characterized by high adoption rates of advanced fertility treatments, driven by progressive healthcare policies and the availability of cutting-edge technologies. California, in particular, leads the region due to its dense network of fertility clinics and a population willing to invest in reproductive health.

Competitive Landscape:

Top players in the market are expanding their operations through strategic acquisitions and partnerships. They are focusing on technological advancements and service expansion for catering to diverse patient needs and enhancing the success rates of fertility treatments. Moreover, they are engaging in funding to introduce advanced products. For instance, on 29 May 2024, Gameto, a New York-based biotechnology company dedicated to advancing treatment options in women's health, raised $33 million Series B financing round to advance the development and commercialization of novel fertility treatments.

The report provides a comprehensive analysis of the competitive landscape in the U.S. in vitro fertilization market with detailed profiles of all major companies.

Latest News and Developments:

• In July 2024, Mira, a US-based hormonal health company, launched an online clinic that aims to provide personalized support from fertility professionals to people struggling to conceive. It focuses on addressing hormonal imbalances, and nutrition and gut health, setting up effective exercise routines and improving mental health.

U.S. in Vitro Fertilization Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the U.S. in vitro fertilization market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the U.S. in vitro fertilization industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.